Targeting KRAS Directly

Literature Cited

1. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z. et al. 1999. Guanosine triphosphatase stimulation of oncogenic Ras mutants. PNAS 96:7065–70 [Google Scholar]
2. Bos JL, Rehmann H, Wittinghofer A. 2007. GEFs and GAPs: critical elements in the control of small G proteins. Cell 129:865–77 [Google Scholar]
3. Bourne HR, Sanders DA, McCormick F. 1991. The GTPase superfamily: conserved structure and molecular mechanism. Nature 349:117–27 [Google Scholar]
4. Cetin M, Evenson WE, Gross GG, Jalali-Yazdi F, Krieger D. et al. 2017. RasIns: genetically encoded intrabodies of activated Ras proteins. J. Mol. Biol. 429:562–73 [Google Scholar]
5. Clark GJ, Drugan JK, Terrell RS, Bradham C, Der CJ. et al. 1996. Peptides containing a consensus Ras binding sequence from Raf-1 and the GTPase activating protein NF1 inhibit Ras function. PNAS 93:1577–81 [Google Scholar]
6. Cox AD, Der CJ, Philips MR. 2015. Targeting RAS membrane association: back to the future for anti-RAS drug discovery?. Clin. Cancer Res. 21:1819–27 [Google Scholar]
7. Feramisco JR, Clark R, Wong G, Arnheim N, Milley R, McCormick F. 1985. Transient reversion of ras oncogene-induced cell transformation by antibodies specific for amino acid 12 of ras protein. Nature 314:639–42 [Google Scholar]
8. Hancock JF, Magee AI, Childs JE, Marshall CJ. 1989. All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57:1167–77 [Google Scholar]
9. Hunter JC, Manandhar A, Carrasco MA, Gurbani D, Gondi S, Westover KD. 2015. Biochemical and structural analysis of common cancer-associated KRAS mutations. Mol. Cancer Res. 13:1325–35 [Google Scholar]
10. Lai AC, Toure M, Hellerschmied D, Salami J, Jaime-Figueroa S. et al. 2016. Modular PROTAC design for the degradation of oncogenic BCR-ABL. Angew. Chem. Int. Ed. 55:807–10 [Google Scholar]
11. Leshchiner ES, Parkhitko A, Bird GH, Luccarelli J, Bellairs JA. et al. 2015. Direct inhibition of oncogenic KRAS by hydrocarbon-stapled SOS1 helices. PNAS 112:1761–66 [Google Scholar]
12. Maurer T, Garrenton LS, Oh A, Pitts K, Anderson DJ. et al. 2012. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. PNAS 109:5299–304 [Google Scholar]
13. Mott HR, Owen D. 2015. Structures of Ras superfamily effector complexes: What have we learnt in two decades?. Crit. Rev. Biochem. Mol. Biol. 50:85–133 [Google Scholar]
14. Nan X, Tamguney TM, Collisson EA, Lin LJ, Pitt C. et al. 2015. Ras-GTP dimers activate the Mitogen-Activated Protein Kinase (MAPK) pathway. PNAS 112:7996–8001 [Google Scholar]
15. Ostrem JM, Peters U, Sos ML, Wells JA, Shokat KM. 2013. K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions. Nature 503:548–51 [Google Scholar]
16. Ostrem JM, Shokat KM. 2016. Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat. Rev. Drug. Discov. 15:771–85 [Google Scholar]
17. Patricelli MP, Janes MR, Li LS, Hansen R, Peters U. et al. 2016. Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state. Cancer Discov 6:316–29 [Google Scholar]
18. Prior IA, Lewis PD, Mattos C. 2012. A comprehensive survey of Ras mutations in cancer. Cancer Res 72:2457–67 [Google Scholar]
19. Quinlan MP, Quatela SE, Philips MR, Settleman J. 2008. Activated Kras, but not Hras or Nras, may initiate tumors of endodermal origin via stem cell expansion. Mol. Cell Biol. 28:2659–74 [Google Scholar]
20. Scheffzek K, Ahmadian MR, Kabsch W, Wiesmuller L, Lautwein A. et al. 1997. The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277:333–38 [Google Scholar]
21. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. 1996. Discovering high-affinity ligands for proteins: SAR by NMR. Science 274:1531–34 [Google Scholar]
22. Spencer-Smith R, Koide A, Zhou Y, Eguchi RR, Sha F. et al. 2017. Inhibition of RAS function through targeting an allosteric regulatory site. Nat. Chem. Biol. 13:62–68 [Google Scholar]
23. Stephen AG, Esposito D, Bagni RK, McCormick F. 2014. Dragging Ras back in the ring. Cancer Cell 25:272–81 [Google Scholar]
24. Sun Q, Burke JP, Phan J, Burns MC, Olejniczak ET. et al. 2012. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. 51:6140–43 [Google Scholar]
25. Sung PJ, Tsai FD, Vais H, Court H, Yang J. et al. 2013. Phosphorylated K-Ras limits cell survival by blocking Bcl-xL sensitization of inositol trisphosphate receptors. PNAS 110:20593–98 [Google Scholar]
26. Tanaka T, Rabbitts TH. 2010. Interfering with RAS–effector protein interactions prevent RAS-dependent tumour initiation and causes stop–start control of cancer growth. Oncogene 29:6064–70 [Google Scholar]
27. Upadhyaya P, Qian Z, Selner NG, Clippinger SR, Wu Z. et al. 2015. Inhibition of Ras signaling by blocking Ras–effector interactions with cyclic peptides. Angew. Chem. Int. Ed. 54:7602–6 [Google Scholar]
28. Villalonga P, Lopez-Alcala C, Bosch M, Chiloeches A, Rocamora N. et al. 2001. Calmodulin binds to K-Ras, but not to H- or N-Ras, and modulates its downstream signaling. Mol. Cell Biol. 21:7345–54 [Google Scholar]
29. Wang MT, Holderfield M, Galeas J, Delrosario R, To MD. et al. 2015. K-Ras promotes tumorigenicity through suppression of non-canonical Wnt signaling. Cell 163:1237–51 [Google Scholar]
30. Wang T, Yu H, Hughes NW, Liu B, Kendirli A. et al. 2017. Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras. Cell 168:890–903.e815 [Google Scholar]
31. Welsch ME, Kaplan A, Chambers JM, Stokes ME, Bos PH. et al. 2017. Multivalent small-molecule pan-RAS inhibitors. Cell 168:878–89.e829 [Google Scholar]
32. Willumsen BM, Christensen A, Hubbert NL, Papageorge AG, Lowy DR. 1984. The p21 ras C-terminus is required for transformation and membrane association. Nature 310:583–86 [Google Scholar]
33. Zhou Y, Prakash P, Liang H, Cho KJ, Gorfe AA, Hancock JF. 2017. Lipid-sorting specificity encoded in K-Ras membrane anchor regulates signal output. Cell 168:239–51.e216 [Google Scholar]
34. Zimmermann G, Papke B, Ismail S, Vartak N, Chandra A. et al. 2013. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497:638–42 [Google Scholar]